Type Gene Administration route Concentration (μg) virus dose Mortality (%) duration (days) Reference
  vp28 intramuscular injection 4 2500 SID50 13 10 [108]
  vp28 intramuscular injection 5 4x10-8 15 10 [111]
  vp28 intramuscular injection 6 1-2 LD50 0 7 [110]
  vp28 oral (coated in feed) n.d n.d 63% 15 [139]
  vp28 oral (chitosan nanoparticles) n.d n.d 32% 15 [139]
Structural vp281 intramuscular injection 6 1-2 LD50 20 - 47% 7 [110]
  vp26 intramuscular injection 4 2500 SID50 21% 10 [108]
  vp26 intramuscular injection 25 1x10-5 100% 30 [140]
  vp24 intramuscular injection 25 1x10-5 37% 30 [140]
  vp19 intramuscular injection 25 1x10-5 66% 30 [140]
  vp15 intramuscular injection 25 1x10-5 37% 30 [140]
  RR2 intramuscular injection 5 4x10-8 22% 10 [111]
Non-structural DNA pol intramuscular injection 5 4x10-8 56% 10 [111]
  PK intramuscular injection 6 1-2 LD50 7% 7 [110]
Legends: SID50 - shrimp infctious dose 50% endpoint, LD50 - lethal dose 50% endpoint. N.d. not determined. RR2 - ribonucleotide reductase small subunit. DNA pol - DNA polymerase. PK - protein kinase.
Table 2: In vivo evaluation of dsRNA efficacy against different WSSV genes encoding structural and non-structural proteins.
Goto home»